Aurinia Pharmaceuticals to Present at the Canaccord Genuity 35th Annual Growth Conference
VICTORIA, British Columbia-- Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX:AUP) today announced that its Chief Operating Officer Michael R. Martin will present a corporate overview of the company at the Canaccord Genuity 35th Annual Growth Conference, taking place August 12-13 in Boston at the Intercontinental Hotel.
Aurinia Presentation Details
Date:
Thursday, August 13, 2015
Time: 9:30 a.m. Eastern
Location:
InterContinental Boston Hotel
Webcast: http://wsw.com/webcast/canaccord18/auph
About Aurinia
Aurinia is a clinical stage
pharmaceutical company focused on the global nephrology market. It is
currently in the recruitment and enrollment phase of its Phase 2b
clinical trial to evaluate the efficacy of its drug, voclosporin, as a
treatment for lupus nephritis (LN). LN is an inflammation of the
kidneys, that if inadequately treated can lead to end-stage renal
disease, making LN a serious and potentially life-threatening condition.
Visit www.auriniapharma.com for more information.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150806005270/en/
Aurinia Pharmaceuticals Inc.
Company Contact:
Stephen
Zaruby, 250-708-4293
President & Chief Executive Officer
szaruby@auriniapharma.com
or
Investor
& Media Contact:
Michael R. Martin, 250-708-4272
Chief
Operating Officer
mmartin@auriniapharma.com
Source: Aurinia Pharmaceuticals, Inc.
Released August 6, 2015
